These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23639874)

  • 1. Novel pharmacotherapies of familial hyperlipidemia.
    Drakopoulou M; Toutouzas K; Stefanadis C
    Pharmacol Ther; 2013 Sep; 139(3):301-12. PubMed ID: 23639874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for hyperlipidaemia: an update.
    Florentin M; Kostapanos MS; Kei A; Elisaf MS
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):471-88. PubMed ID: 25356785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.
    Ooi EM; Barrett PH; Watts GF
    Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatments on the horizon for familial hypercholesterolemia.
    Allian-Sauer MU; Falko JM
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1227-37. PubMed ID: 23190063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
    Lee WP; Datta BN; Ong BB; Rees A; Halcox J
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1229-1234. PubMed ID: 33070644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH; Chapman MJ; Kontush A
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
    Cuchel M; Bloedon LT; Szapary PO; Kolansky DM; Wolfe ML; Sarkis A; Millar JS; Ikewaki K; Siegelman ES; Gregg RE; Rader DJ
    N Engl J Med; 2007 Jan; 356(2):148-56. PubMed ID: 17215532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
    Santos RD
    Atheroscler Suppl; 2014 Sep; 15(2):19-25. PubMed ID: 25257073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
    Stefanutti C; Julius U; Watts GF; Harada-Shiba M; Cossu M; Schettler VJ; De Silvestro G; Soran H; Van Lennep JR; Pisciotta L; Klör HU; Widhalm K; Moriarty PM;
    J Clin Lipidol; 2017; 11(4):858-871.e3. PubMed ID: 28572002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational therapies for the treatment of atherosclerosis.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
    Rizzo M
    IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
    Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies and new targets of treatment for familial hypercholesterolemia.
    Goldberg AC
    J Clin Lipidol; 2010; 4(5):350-6. PubMed ID: 21122677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.